Fiblast (Trafermin) in Acute Stroke: Results of the European-Australian Phase II/III Safety and Efficacy Trial

Background: Trafermin (basic fibroblast growth factor) has been shown to reduce infarct volume in acute ischemic stroke models, and to promote functional recovery and new synapse formation when given to animals with completed cerebral infarction. A previous study in acute stroke patients suggested t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cerebrovascular diseases (Basel, Switzerland) Switzerland), 2002-01, Vol.14 (3-4), p.239-251
Hauptverfasser:	Bogousslavsky, Julien, Victor, Stephen J., Salinas, Eliseo O., Pallay, Allan, Donnan, Geoffrey A., Fieschi, Cesare, Kaste, Markku, Orgogozo, Jean-Marc, Chamorro, Angel, Desmet, Anne
Format:	Artikel
Sprache:	eng
Schlagworte:	Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Fibroblast Growth Factors - administration & dosage Fibroblast Growth Factors - adverse effects Fibroblast Growth Factors - therapeutic use Humans Infusions, Intravenous Original Paper Peptide Fragments - administration & dosage Peptide Fragments - adverse effects Peptide Fragments - therapeutic use Safety Stroke - drug therapy Stroke - physiopathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!